Literature DB >> 16254354

Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins.

Gene G Olinger1, Michael A Bailey, John M Dye, Russell Bakken, Ana Kuehne, John Kondig, Julie Wilson, Robert J Hogan, Mary Kate Hart.   

Abstract

Infection with Ebola virus causes a severe disease accompanied by high mortality rates, and there are no licensed vaccines or therapies available for human use. Filovirus vaccine research efforts still need to determine the roles of humoral and cell-mediated immune responses in protection from Ebola virus infection. Previous studies indicated that exposure to Ebola virus proteins expressed from packaged Venezuelan equine encephalitis virus replicons elicited protective immunity in mice and that antibody-mediated protection could only be demonstrated after vaccination against the glycoprotein. In this study, the murine CD8(+) T-cell responses to six Ebola virus proteins were examined. CD8(+) T cells specific for Ebola virus glycoprotein, nucleoprotein, and viral proteins (VP24, VP30, VP35, and VP40) were identified by intracellular cytokine assays using splenocytes from vaccinated mice. The cells were expanded by restimulation with peptides and demonstrated cytolytic activity. Adoptive transfer of the CD8(+) cytotoxic T cells protected filovirus naïve mice from challenge with Ebola virus. These data support a role for CD8(+) cytotoxic T cells as part of a protective mechanism induced by vaccination against six Ebola virus proteins and provide additional evidence that cytotoxic T-cell responses can contribute to protection from filovirus infections.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16254354      PMCID: PMC1280180          DOI: 10.1128/JVI.79.22.14189-14196.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

Review 1.  Quantitative aspects of T cell activation--peptide generation and editing by MHC class I molecules.

Authors:  S Stevanović; H Schild
Journal:  Semin Immunol       Date:  1999-12       Impact factor: 11.130

2.  Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein.

Authors:  J A Wilson; M K Hart
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

3.  The Ebola virus VP35 protein functions as a type I IFN antagonist.

Authors:  C F Basler; X Wang; E Mühlberger; V Volchkov; J Paragas; H D Klenk; A García-Sastre; P Palese
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

4.  A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding.

Authors:  R N Harty; M E Brown; G Wang; J Huibregtse; F P Hayes
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

5.  Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication.

Authors:  M Gupta; S Mahanty; M Bray; R Ahmed; P E Rollin
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

6.  Vesicular release of ebola virus matrix protein VP40.

Authors:  J Timmins; S Scianimanico; G Schoehn; W Weissenhorn
Journal:  Virology       Date:  2001-04-25       Impact factor: 3.616

7.  Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses.

Authors:  Steven M Jones; Heinz Feldmann; Ute Ströher; Joan B Geisbert; Lisa Fernando; Allen Grolla; Hans-Dieter Klenk; Nancy J Sullivan; Viktor E Volchkov; Elizabeth A Fritz; Kathleen M Daddario; Lisa E Hensley; Peter B Jahrling; Thomas W Geisbert
Journal:  Nat Med       Date:  2005-06-05       Impact factor: 53.440

8.  The role of the Type I interferon response in the resistance of mice to filovirus infection.

Authors:  Mike Bray
Journal:  J Gen Virol       Date:  2001-06       Impact factor: 3.891

9.  Development of a preventive vaccine for Ebola virus infection in primates.

Authors:  N J Sullivan; A Sanchez; P E Rollin; Z Y Yang; G J Nabel
Journal:  Nature       Date:  2000-11-30       Impact factor: 49.962

10.  Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus.

Authors:  P Pushko; M Bray; G V Ludwig; M Parker; A Schmaljohn; A Sanchez; P B Jahrling; J F Smith
Journal:  Vaccine       Date:  2000-08-15       Impact factor: 3.641

View more
  42 in total

Review 1.  Filovirus vaccines.

Authors:  Steven B Bradfute; John M Dye; Sina Bavari
Journal:  Hum Vaccin       Date:  2011-06-01

2.  Combined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitis viruses.

Authors:  Douglas S Reed; Pamela J Glass; Russell R Bakken; James F Barth; Cathleen M Lind; Luis da Silva; Mary Kate Hart; Jonathan Rayner; Kim Alterson; Max Custer; Jeanne Dudek; Gary Owens; Kurt I Kamrud; Michael D Parker; Jonathan Smith
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

3.  Vaccinating captive chimpanzees to save wild chimpanzees.

Authors:  Kelly L Warfield; Jason E Goetzmann; Julia E Biggins; Mary Beth Kasda; Robert C Unfer; Hong Vu; M Javad Aman; Gene Gerrard Olinger; Peter D Walsh
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-27       Impact factor: 11.205

4.  Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.

Authors:  Adrián Lázaro-Frías; Sergio Gómez-Medina; Lucas Sánchez-Sampedro; Karl Ljungberg; Mart Ustav; Peter Liljeström; César Muñoz-Fontela; Mariano Esteban; Juan García-Arriaza
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

5.  Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.

Authors:  Zhen-Yong Keck; Sven G Enterlein; Katie A Howell; Hong Vu; Sergey Shulenin; Kelly L Warfield; Jeffrey W Froude; Nazli Araghi; Robin Douglas; Julia Biggins; Calli M Lear-Rooney; Ariel S Wirchnianski; Patrick Lau; Yong Wang; Andrew S Herbert; John M Dye; Pamela J Glass; Frederick W Holtsberg; Steven K H Foung; M Javad Aman
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

Review 6.  Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates.

Authors:  John J Suschak; Connie S Schmaljohn
Journal:  Hum Vaccin Immunother       Date:  2019-10-07       Impact factor: 3.452

7.  Replication-deficient ebolavirus as a vaccine candidate.

Authors:  Peter Halfmann; Hideki Ebihara; Andrea Marzi; Yasuko Hatta; Shinji Watanabe; M Suresh; Gabriele Neumann; Heinz Feldmann; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

8.  High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon.

Authors:  Pierre Becquart; Nadia Wauquier; Tanel Mahlakõiv; Dieudonné Nkoghe; Cindy Padilla; Marc Souris; Benjamin Ollomo; Jean-Paul Gonzalez; Xavier De Lamballerie; Mirdad Kazanji; Eric M Leroy
Journal:  PLoS One       Date:  2010-02-09       Impact factor: 3.240

9.  Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola.

Authors:  Devon J Shedlock; Jenna Aviles; Kendra T Talbott; Gary Wong; Stephan J Wu; Daniel O Villarreal; Devin Jf Myles; Maria A Croyle; Jian Yan; Gary P Kobinger; David B Weiner
Journal:  Mol Ther       Date:  2013-05-14       Impact factor: 11.454

10.  Discovery of common marburgvirus protective epitopes in a BALB/c mouse model.

Authors:  Warren V Kalina; Kelly L Warfield; Gene G Olinger; Sina Bavari
Journal:  Virol J       Date:  2009-08-27       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.